Endocrine changes after laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovarian syndrome.
OBJECTIVE
To study the effects of laparoscopic ovarian drilling on the serum hormone levels in clomiphene citrate resistant women with polycystic ovarian syndrome (PCOS) and to determine the criteria which influenced their clinical response.


METHODS
A prospective study that was carried out at Salmaniya Medical Complex in Bahrain. One hundred and eighty-one women with clomiphene citrate-resistant PCOS were treated with laparoscopic ovarian drilling, all procedures were performed over a 4-year period between June 1996 and June 2000. Fasting blood samples for determination of the serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), LH-FSH ratio, testosterone and prolactin were taken during the follicular phase before and one month after laparoscopic ovarian drilling.


RESULTS
Responders who ovulated spontaneously after the drilling were obese and had higher preoperative LH levels and the LH-FSH ratio. Both responders and non-responders showed a significant decline in LH, LH-FSH ratio and testosterone with a significant increase in FSH but no significant change in prolactin mean values compared with pretreatment levels. The magnitude of change was significantly higher for LH and the LH-FSH ratio (p<0.05) in responders, while there were no significant differences in the corresponding values of the other hormones between the 2 groups. Moreover, the decrease in LH (p<0.01) and the LH-FSH ratio (p<0.05) was significantly greater in obese than non-obese women and this was only observed in the responders group.


CONCLUSIONS
Laparoscopic ovarian drilling is an effective procedure in women with clomiphene citrate resistant PCOS. It produces significant endocrine changes with better results in obese patients with higher preoperative LH values and LH-FSH ratio. The magnitude of these changes was the highest in obese responders.
Department of Obstetrics and Gynecology, Salmaniya Medical Complex, Ministry of Health, PO Box 20470, Manama, Bahrain. eftekharojaimi15@hotmail.com
Eftekhar H
EH
Al-Ojaimi
D000328:Adult; D002996:Clomiphene / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004703:Endocrine System / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000502:physiology; D009765:Obesity / Q000150:complications; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler
D006728:Hormones; D002996:Clomiphene; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone